Phospho-ACO1 (S138) Antibody

What is ACO1 and what is the significance of its S138 phosphorylation site?

Aconitase 1 (ACO1), also known as Iron Regulatory Protein 1 (IRP1), is a bifunctional protein that serves dual roles in cellular metabolism. In its holo-form, ACO1 contains a [4Fe-4S] cluster and functions as an aconitase enzyme that catalyzes the conversion of citrate to isocitrate in the citric acid cycle. In its apo-form (without the iron-sulfur cluster), it functions as an RNA-binding protein that regulates the expression of genes involved in iron uptake, sequestration, and utilization . The S138 phosphorylation site is particularly significant because it serves as a regulatory switch that influences the balance between these two functions. Research has demonstrated that phosphorylation at S138 destabilizes the [4Fe-4S] cluster, promoting the RNA-binding form of ACO1 over its aconitase activity . This phosphorylation is primarily mediated by Protein Kinase C (PKC) and represents a mechanism for iron-independent regulation of ACO1/IRP1 function .

How does S138 phosphorylation specifically affect the [4Fe-4S] cluster stability?

Experimental evidence demonstrates that phosphorylation of ACO1/IRP1 at S138 selectively affects its aconitase function by destabilizing the [4Fe-4S] cluster . When S138 is phosphorylated or replaced with phosphomimetic amino acids (such as glutamate or aspartate), the [4Fe-4S] cluster becomes significantly more susceptible to oxidative degradation. Studies using purified ACO1 proteins have shown that phosphomimetic mutants (S138E and S138D) experience accelerated [4Fe-4S] cluster decay when exposed to oxygen—the S138D mutant showing a 5-fold faster decay rate and the S138E mutant showing a 20-fold faster decay rate compared to wild-type ACO1 . This enhanced susceptibility to oxidative degradation effectively shifts the balance toward the RNA-binding form of ACO1/IRP1, even under conditions where iron availability would otherwise favor the aconitase function . The molecular mechanism likely involves conformational changes that expose the [4Fe-4S] cluster to oxidative attack or alter the protein's interaction with iron-sulfur cluster assembly machinery.

What are the validated applications for Phospho-ACO1 (S138) antibodies?

Phospho-ACO1 (S138) antibodies have been validated for several experimental applications, as summarized in the table below:

These antibodies have been demonstrated to react with human, mouse, and rat samples, making them valuable tools for comparative studies across these species . The high specificity of these antibodies has been confirmed through the use of phosphorylation site mutants (S138A) as negative controls, ensuring that the antibodies specifically recognize the phosphorylated form of S138 rather than total ACO1 protein . When selecting a Phospho-ACO1 (S138) antibody, researchers should consider their specific experimental requirements and the validation data provided by manufacturers to ensure optimal results.

What is the interplay between S138 phosphorylation and other ACO1 phosphorylation sites?

ACO1/IRP1 contains multiple phosphorylation sites that collectively regulate its function in iron metabolism. While S138 phosphorylation primarily affects [4Fe-4S] cluster stability, another key site, S711, has been shown to selectively inhibit the citrate-to-isocitrate reaction of cytosolic aconitase without affecting the isocitrate-to-citrate direction . This creates a complex regulatory network where different phosphorylation events can fine-tune specific aspects of ACO1/IRP1 function. Research using phosphorylation state-specific antibodies has demonstrated that S711 is also phosphorylated by PKC, both in vitro and in cells treated with phorbol 12-myristate 13-acetate (PMA) . Studies with phosphomimetic mutations at S711 (S711D and S711E) showed that these mutants were unable to rescue aco1 yeast from glutamate auxotrophy, supporting the concept that phosphorylation at S711 specifically impairs the conversion of citrate to isocitrate . The distinct but complementary effects of S138 and S711 phosphorylation suggest that these modifications may work together to regulate ACO1/IRP1 function in response to different cellular signals, providing a mechanism for iron-independent modulation of iron metabolism and citric acid cycle activity.

What are the optimal protocols for using Phospho-ACO1 (S138) antibodies in different experimental settings?

When using Phospho-ACO1 (S138) antibodies, researchers should optimize their protocols based on the specific experimental application. For Western blot analysis, it is recommended to use fresh or properly stored (at -80°C) cell lysates to prevent dephosphorylation by endogenous phosphatases. Including phosphatase inhibitors in lysis buffers is critical for preserving phosphorylation status. For immunoprecipitation experiments, a validated approach involves using recombinant ACO1/IRP1 proteins or the S138A mutant as negative controls to confirm antibody specificity . For immunohistochemistry applications, a dilution range of 1:100-1:300 has been validated, with antigen retrieval methods optimized for phospho-epitopes . For immunofluorescence studies, dilutions of 1:200-1:1000 have shown optimal results . In all applications, researchers should include appropriate controls, including non-phosphorylated ACO1/IRP1 and S138A mutants, to validate the specificity of the antibody for the phosphorylated form. Additionally, researchers should consider using total ACO1/IRP1 antibodies in parallel to distinguish between changes in phosphorylation status and changes in total protein levels.

What controls should be included when using Phospho-ACO1 (S138) antibodies for functional studies?

When conducting functional studies with Phospho-ACO1 (S138) antibodies, several essential controls should be included to ensure valid and interpretable results:

• Phosphorylation-site mutants: The S138A mutant of ACO1/IRP1, which cannot be phosphorylated at position 138, serves as a critical negative control for antibody specificity . This control helps distinguish between specific antibody binding to phosphorylated S138 and non-specific binding to other phosphorylated residues or protein regions.

• Dephosphorylated samples: Treating samples with lambda phosphatase prior to antibody incubation can confirm that the antibody specifically recognizes the phosphorylated form of ACO1/IRP1.

• Blocking peptides: Using synthetic phosphopeptides that correspond to the S138 region can serve as competition controls to verify antibody specificity .

• Total ACO1/IRP1 detection: Parallel detection of total ACO1/IRP1 protein levels is essential to distinguish between changes in phosphorylation status and changes in protein expression or stability.

• Functional readouts: Correlating phosphorylation status with functional outcomes, such as aconitase activity or RNA-binding capacity, provides important validation of the biological relevance of detected phosphorylation events.

Including these controls ensures that observed changes in S138 phosphorylation are specific, biologically relevant, and correctly interpreted in the context of ACO1/IRP1's dual functionality.

How should researchers interpret discrepancies between phospho-antibody detection and functional assays?

Discrepancies between phospho-antibody detection and functional assays of ACO1/IRP1 are not uncommon and require careful interpretation. Several factors may contribute to such discrepancies. First, the relationship between S138 phosphorylation and ACO1/IRP1 function is not linear or absolute—while phosphorylation at S138 promotes the RNA-binding form by destabilizing the [4Fe-4S] cluster, this effect is modulated by other factors including oxygen levels, cellular iron status, and additional post-translational modifications . Second, the temporal dynamics of phosphorylation versus functional changes may differ; phosphorylation can occur rapidly, while [4Fe-4S] cluster disassembly and the resulting functional switch may take longer. Third, the stoichiometry of phosphorylation matters—antibodies may detect even low levels of S138 phosphorylation, but functional effects may only become apparent when a significant proportion of the protein is phosphorylated.

To address these interpretive challenges, researchers should combine multiple approaches: (1) quantify the ratio of phosphorylated to total ACO1/IRP1; (2) perform time-course experiments to capture the temporal relationship between phosphorylation and functional changes; (3) use phosphomimetic and phospho-deficient mutants to establish causative relationships; and (4) consider the broader cellular context, including iron availability, oxidative stress, and other signaling pathways that may influence ACO1/IRP1 function independently of S138 phosphorylation.

What are the key considerations when interpreting the effects of phosphomimetic mutations on ACO1/IRP1 function?

When interpreting the effects of phosphomimetic mutations (S138D, S138E) on ACO1/IRP1 function, researchers should consider several important factors. First, while these mutations mimic many aspects of phosphorylation, they do not perfectly replicate the biophysical properties of a phosphorylated serine. Studies have shown that the S138E mutation results in a more dramatic destabilization of the [4Fe-4S] cluster (20-fold faster decay) compared to the S138D mutation (5-fold faster decay) , suggesting that the specific phosphomimetic amino acid chosen can significantly influence the experimental outcome. Second, phosphomimetic mutations represent a constitutive "phosphorylated" state, whereas physiological phosphorylation is dynamic and regulated. This distinction is particularly important when interpreting experiments involving cellular signaling or temporal responses. Third, phosphomimetic mutations may have different effects depending on the experimental system—studies in yeast, purified proteins, and mammalian cells have shown some consistent effects but also system-specific differences .

To address these challenges, researchers should: (1) compare multiple phosphomimetic mutations (S138D, S138E) to identify consistent effects; (2) validate findings with phospho-specific antibodies in systems where dynamic phosphorylation occurs; (3) consider complementary approaches such as in vitro phosphorylation of purified proteins; and (4) correlate mutational effects with established functional readouts of ACO1/IRP1 activity, such as aconitase enzymatic assays or RNA binding measurements.

How do cell type-specific differences affect the interpretation of S138 phosphorylation data?

Cell type-specific differences can significantly influence the interpretation of S138 phosphorylation data due to variations in iron metabolism, PKC signaling pathways, and oxidative stress responses across different cell types. Research has shown that the RNA-binding form of ACO1/IRP1 is a preferred substrate for PKC-dependent phosphorylation, suggesting that the baseline distribution between the aconitase and RNA-binding forms—which can vary by cell type—may affect the extent and consequences of S138 phosphorylation . Additionally, cell types differ in their expression of proteins involved in iron-sulfur cluster assembly and iron metabolism, which can modulate the effects of S138 phosphorylation on ACO1/IRP1 function.

When interpreting cell type-specific data, researchers should consider: (1) the baseline iron status and metabolic characteristics of the cell type; (2) the expression levels of proteins involved in iron-sulfur cluster assembly, such as ISCU, frataxin, and components of the cytosolic iron-sulfur cluster assembly (CIA) pathway ; (3) the activity of relevant signaling pathways, particularly PKC; and (4) the oxidative environment of the cell type, which can influence [4Fe-4S] cluster stability independently of phosphorylation. Comparative studies across multiple cell types or primary tissues can help distinguish cell type-specific effects from general mechanisms of ACO1/IRP1 regulation by S138 phosphorylation.

What are the emerging techniques for studying ACO1/IRP1 phosphorylation dynamics?

Recent advances in phosphoproteomic technologies are opening new avenues for studying ACO1/IRP1 phosphorylation dynamics with unprecedented resolution. Mass spectrometry-based approaches, particularly parallel reaction monitoring (PRM), have emerged as powerful tools for tracking the phosphorylation dynamics of specific sites like S138 in response to various stimuli . These targeted methods allow for sensitive and quantitative monitoring of phosphorylation events over time, providing insights into the kinetics and stoichiometry of ACO1/IRP1 phosphorylation. Another promising approach involves hydrogen-deuterium exchange mass spectrometry (HDX-MS), which has been successfully used to characterize conformational dynamics in protein kinases and could reveal how S138 phosphorylation alters the structural dynamics of ACO1/IRP1 .

Genetically encoded biosensors represent another frontier in studying phosphorylation dynamics in live cells. While not yet specifically developed for ACO1/IRP1, phosphorylation-specific biosensors based on fluorescence resonance energy transfer (FRET) or bioluminescence resonance energy transfer (BRET) could provide real-time visualization of S138 phosphorylation in living cells. The development of such tools would enable researchers to correlate phosphorylation events with functional outcomes at the single-cell level, offering unprecedented insights into the temporal and spatial dynamics of ACO1/IRP1 regulation.

How might the understanding of S138 phosphorylation contribute to therapeutic interventions?

The detailed understanding of S138 phosphorylation in regulating ACO1/IRP1 function has potential implications for therapeutic interventions targeting iron metabolism disorders, neurodegenerative diseases, and cancer. Dysregulation of iron metabolism is implicated in various pathological conditions, including hereditary hemochromatosis, Friedreich's ataxia, and certain neurodegenerative disorders like Parkinson's and Alzheimer's diseases. Given that S138 phosphorylation provides an iron-independent mechanism for modulating ACO1/IRP1 function, therapeutic approaches targeting this phosphorylation site could potentially restore balanced iron metabolism in conditions where traditional iron-based regulation is compromised.

In cancer biology, the dual role of ACO1/IRP1 in iron metabolism and the citric acid cycle intersects with the metabolic reprogramming characteristic of many tumors. Targeting S138 phosphorylation could potentially influence both metabolic pathways and iron availability to cancer cells, offering a novel approach to cancer therapy. Additionally, the link between S138 phosphorylation and oxygen sensitivity suggests potential applications in ischemia-reperfusion injuries, where oxygen levels fluctuate dramatically and iron-mediated oxidative damage plays a significant role. Future research should focus on developing small molecules or peptides that can modulate S138 phosphorylation or mimic its effects on ACO1/IRP1 function in a targeted manner, potentially opening new therapeutic avenues for a range of diseases involving iron dysregulation or metabolic perturbations.